{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:18Z","timestamp":1790272158482,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eclinm.2023.102167","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T23:47:30Z","timestamp":1693266450000},"page":"102167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7750-4359","authenticated-orcid":false,"given":"Kaz","family":"Groen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.M.","family":"Stege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-5015","authenticated-orcid":false,"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"de Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel J.W.","family":"van Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rineke B.L.","family":"Leys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Lung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila E.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjo A.","family":"Velders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christiane","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert-Jan","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fransien","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine W.","family":"Tick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Verbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Buitenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"van der Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther G.M.","family":"de Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Sohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger S.","family":"Nijhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-2704","authenticated-orcid":false,"given":"Saskia K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.eclinm.2023.102167_bib1","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10218","key":"10.1016\/j.eclinm.2023.102167_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.eclinm.2023.102167_bib3","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.eclinm.2023.102167_bib4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.eclinm.2023.102167_bib5","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102167_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A\u00a0simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the first (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102167_bib7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102167_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102167_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.eclinm.2023.102167_bib10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102167_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102167_bib12","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102167_bib13","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102167_bib14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.eclinm.2023.102167_bib15","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102167_bib16","series-title":"Common Terminology criteria for adverse events (CTCAE) version 4.0","year":"2009"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102167_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"34","key":"10.1016\/j.eclinm.2023.102167_bib18","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102167_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"15_suppl","key":"10.1016\/j.eclinm.2023.102167_bib20","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2018.36.15_suppl.10009","article-title":"Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT)","volume":"36","author":"Celis","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10168","key":"10.1016\/j.eclinm.2023.102167_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.eclinm.2023.102167_bib22","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102167_bib23","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3324\/haematol.2019.240374","volume":"105","author":"Zweegman","year":"2020","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.eclinm.2023.102167_bib24","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102167_bib25","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102167_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102167_bib27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/jnci\/djy169","article-title":"Expanding the evidence base in geriatric oncology: action items from an FDA-ASCO workshop","volume":"110","author":"Levit","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102167_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056147","article-title":"Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial","volume":"12","author":"Coulson","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102167_bib29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and\u00a0skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102167_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:58Z","timestamp":1762899718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"alternative-id":["S2589537023003449"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102167","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102167"}}